Why bother with the goose if you’ve got the golden egg? That seems to be the philosophy governing Exelixis’s stock-for-stock acquisition of Genomica, valued at $110 million. The acquisition was no surprise to industry watchers after the bioinformatics software company laid off 100 of its 150-person staff last October — just three weeks after some people were hired.
Acquisition Cash and Carry
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.